At one center, enrollment was delayed, no children from that middle were one of the primary 6000 enrolled. At another center, research vaccines were subjected to temperatures beyond your recommended storage range, resulting in the exclusion of 870 children from the per-protocol evaluation. The first 200 individuals from each center contributed to the evaluation of reactogenicity and immunogenicity. In total, 15,460 participants were enrolled, including 6537 infants 6 to 12 weeks of age and 8923 children 5 to 17 months of age at the time of the 1st vaccination . The mean follow-up moments were 9 months in the younger age category and 1. 5 years in the older age group category after the administration of the 1st dose of a study vaccine . Baseline demographic features were similar in the two study groups .There were seven randomized, managed trials comparing CABG with balloon angioplasty,12-18 four comparing CABG with PCI and keeping bare-metal stents, 19-22 and one comparing CABG with positioning and PCI of drug-eluting stents.2 A survival benefit with CABG was seen in the Stent or Medical procedures trial 23 and in the subgroup with treated diabetes in the Bypass Angioplasty Revascularization Intervention trial .24 A meta-analysis of the trials, including 7812 patients, showed a development toward a survival benefit with CABG.1 In a subgroup analysis according to the absence or existence of diabetes, there is a survival advantage with CABG among individuals who got diabetes, whereas there was no significant advantage among patients who did not have diabetes.